Drug development has languished despite the burden of heart disease. Cardurion has two drug candidates in mid-stage clinical ...

Moderna MRNA has risen 22.1% in the year-to-date period against the industry’s 2.7% fall, as seen in the chart below. The ...

Moderna's mRNA platform now features a long list of candidates, and the biotech still has enough cash on hand -- $12.2 ...

Shares of Moderna Inc. MRNA inched 0.02% higher to $121.48 Monday, on what proved to be an all-around great trading session ...

The company, Moderna Inc, is set to host investors and clients on a conference call on 8/1/2024 12:00:56 PM. The call comes after the company's ...

Moderna has won U.S. Food and Drug Administration approval for its respiratory syncytial virus vaccine mResvia, ushering in a new era for the ...

Flagship scours labs, research hospitals, and universities for cutting-edge science and builds companies around that science.

Local life sciences companies like Moderna Inc. and Takeda Pharmaceuticals Inc. are leaning into AI to help employees work ...

Following a disappointing IPO and the loss of Moderna’s gene editing contract, Metagenomi’s Chief Scientific Officer Luis ...

New York, New York-- (Newsfile Corp. - July 16, 2024) - Pomerantz LLP is investigating claims on behalf of investors of ...

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine ...

Shares of Moderna Inc. MRNA rallied 1.18% to $117.44 Wednesday, on what proved to be an all-around great trading session for ...